Cempra Inc (NASDAQ:CEMP) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.70.

A number of research firms have recently commented on CEMP. Roth Capital upgraded Cempra from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $8.00 to $2.50 in a research note on Monday, February 27th. Robert W. Baird reiterated an “underperform” rating on shares of Cempra in a research note on Tuesday, March 28th. Vetr cut Cempra from a “hold” rating to a “sell” rating and set a $4.07 target price on the stock. in a research note on Monday, March 27th. Jefferies Group LLC reiterated an “underperform” rating and set a $2.00 target price on shares of Cempra in a research note on Wednesday, March 1st. Finally, Zacks Investment Research cut Cempra from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd.

Shares of Cempra (CEMP) opened at 3.84 on Tuesday. Cempra has a 12 month low of $2.55 and a 12 month high of $26.95. The company’s market cap is $201.61 million. The stock has a 50 day moving average of $3.88 and a 200-day moving average of $4.26.

Cempra (NASDAQ:CEMP) last released its earnings results on Friday, April 28th. The biotechnology company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.16. The company had revenue of $4.87 million for the quarter, compared to analysts’ expectations of $3.55 million. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. During the same period in the previous year, the business posted ($0.61) EPS. On average, analysts forecast that Cempra will post ($1.06) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Cempra Inc (CEMP) Receives Consensus Rating of “Hold” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/06/cempra-inc-cemp-receives-consensus-rating-of-hold-from-analysts.html.

In related news, Director Dov A. Md Goldstein sold 150,000 shares of the business’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $3.55, for a total value of $532,500.00. Following the sale, the director now directly owns 95 shares in the company, valued at approximately $337.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 17.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of Cempra by 85.8% in the fourth quarter. State Street Corp now owns 2,133,275 shares of the biotechnology company’s stock worth $5,973,000 after buying an additional 985,427 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Cempra by 175.0% in the first quarter. Renaissance Technologies LLC now owns 1,680,500 shares of the biotechnology company’s stock worth $6,302,000 after buying an additional 1,069,300 shares in the last quarter. Bogle Investment Management L P DE boosted its stake in shares of Cempra by 607.0% in the first quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 609,168 shares in the last quarter. South Dakota Investment Council boosted its stake in shares of Cempra by 19.6% in the first quarter. South Dakota Investment Council now owns 706,207 shares of the biotechnology company’s stock worth $2,648,000 after buying an additional 115,707 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Cempra by 4.6% in the first quarter. Geode Capital Management LLC now owns 394,685 shares of the biotechnology company’s stock worth $1,480,000 after buying an additional 17,181 shares in the last quarter. Institutional investors and hedge funds own 79.92% of the company’s stock.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.